Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Yonsei University200 enrolled

Overview

In general, brain metastases found after development of neurologic symptoms have poor prognosis. Therefore, the investigators aim to investigate whether regular brain MRI (Magnetic Resonance Imaging) can detect early brain metastases and influence survival through early brain management in HER2-positive and triple negative breast cancer.

It is well known that HER2-receptor positive and triple negative metastatic breast cancer (MBC) have poor prognosis than hormone receptor positive metastatic breast cancer. However, as new therapies such as trastuzumab and pertuzumab are introduced, overall survival was extended in patients with metastatic breast cancer compared with the previous 10 years. As a result, the number of breast cancer patients with brain metastases has increased, the demand for treatments of brain metastases is increasing. The incidence of brain metastases in MBC has been reported to be 7.6% and 10.8% in luminal A / B, respectively. However, HER2-positive and triple negative breast cancer with the incidence of more than 30% of brain metastases were at high risk group of brain metastases. In general, brain metastases found after development of neurologic symptoms have poor prognosis. Therefore, the investigators aim to investigate whether regular brain MRI (Magnetic Resonance Imaging) can detect early brain metastases and influence survival through early brain management in HER2-positive and triple negative breast cancer.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Metastatic Breast Cancer With HER2 Positive Triple Negative Breast Cancer

Interventions

Brain MRIPROCEDURE

Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 19 years * Pathologically documented breast cancer that: 1. is unresectable or metastatic ; 2. has confirmed HER2 positive expression according to American Society of Clinical Oncology- College of American Pathologists (ASCO-CAP) guidelines or triple negative breast cancer * No prior systemic palliative treatment of metastatic breast cancer * Must have provided informed consent for study participation before performance of any study-specific procedures or tests Exclusion Criteria: * History of prior treatments about brain metastases or leptomeningeal metastases * Symptomatic brain metastases at screening period * Has received more than second-line systemic treatments (including endocrine therapy) * For subjects who have difficulty lying down or who have claustrophobia, they can undergo sedation during brain MRI * History of hypersensitivity reaction to contrast or drug allergic reaction * Patients who inserted metallic prosthesis (pacemaker, denture, hearing aid, aneurysm clip, metallic material of eyeball, artificial joint, insulin pump, chemo-port, temporary tissue expander for breast reconstruction, etc) can be conducted after consultation with investigator before MRI. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Social, familial, or geographical factors that would interfere with study participation or follow-up

Locations (1)

Yonsei Cancer Center, Severance Hospital, Yonsei University Health System

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

The incidence rates of brain metastases with high risk patients in metastatic breast cancer

The incidence rates of brain metastases with high risk patients in metastatic breast cancer at initial diagnosis and failure of first- and second-line treatments confirmed by brain MRI

Time frame: 5 years

Secondary Outcomes

The incidence rate of brain oligometastasis (≤ 4) confirmed by brain MRI

To evaluate the incidence rate of brain oligometastsais (≤ 4) confirmed by brain MRI

Time frame: 5 years

Intracranial progression free survival(PFS) after treatment of brain metastases

To evaluate intracranial progression free survival(PFS) after treatment of brain metastases

Time frame: 5 years

The overall survival (OS) after diagnosis to brain metastases

To evaluate the overall survival (OS) after diagnosis to brain metastases

Time frame: 5 years

The period from diagnosis to treatment of brain metastases

To evaluate the period from diagnosis to treatment of brain metastases

Time frame: 5 years

The cognitive impairment assessment after brain metastases

To evaluate the cognitive impairment assessment after brain metastases

Time frame: 5 years

Central Contacts

Joohyuk Sohn, MD, Ph.D

CONTACT

82-2-2228-8130 oncosohn@yuhs.ac

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.